← Eichor
Condition: Medulloblastoma Recurrent Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Medulloblastoma Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase 2 · 24 location(s) · Giselle Sholler · NCT04696029A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refra
EARLY_Phase 1 · 1 location(s) · Children's National Research Institute · NCT07017816Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients
Phase 1 · 1 location(s) · University of Florida · NCT06514898Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma
Phase N/A · 1 location(s) · West China Hospital · NCT07660458PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Phase 2 · 13 location(s) · Nationwide Children's Hospital · NCT05096481PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161519GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Phase 1 · 1 location(s) · Stanford University · NCT07087002Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Phase 2 · 1 location(s) · Beijing Sanbo Brain Hospital · NCT04501718Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Phase N/A · 2 location(s) · Mohammad H. Abu Arja · NCT07242963A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliom
Phase 1 · 1 location(s) · Seattle Children's Hospital · NCT04185038Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
NA · 8 location(s) · University of California, San Francisco · NCT05057702Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Phase 1/Phase 2 · 4 location(s) · Nationwide Children's Hospital · NCT05278208HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 · 3 location(s) · M.D. Anderson Cancer Center · NCT03911388A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07698899RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
Phase 1 · 1 location(s) · University of Florida · NCT07492316Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Phase 2 · 22 location(s) · Medical University of Vienna · NCT01356290
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.